Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.

PDTrialTracker.info

12 dyskinesia trials as of 5/21/19

5 telemedicine trials

as of 5/21/19

10 alpha synuclein trials as of 5/21/19

PHASE Not Applicable*

60+ trials per "Review of disease modifying therapies" document*

PHASE 3

*

      Completed Interventional PD Studies Registered on ClinicalTrials.gov (2000-2019)

... and click on country/state to view trial listings.

      CLINICAL TRIALS BY THERAPY FOCUS

      CLINICAL TRIALS BY PHASE

* 28 trials are combined Phase 1/Phase 2 OR combined Phase 2/3. 

Note: 497 total active trials includes 304 recruiting, 78 not yet recruiting, 25 enrolling by invitation and 90 no longer recruiting.

An INTERVENTIONAL STUDY (or Clinical Trial) is a clinical study in which participants are assigned an intervention such as a medication, device, or procedure, so that researchers can evaluate its effects on biomedical or health-related outcomes.  Participants may receive diagnostic, therapeutic, or other types of interventions.  See trial phase descriptions at bottom of page. 

(source: https://clinicaltrials.gov/ct2/about-studies/glossary#I)


497 active PD interventional studies worldwide are registered on ClinicalTrials.gov, as of May 21, 2019. 

Active studies include trials that are recruiting, not yet recruiting, enrolling by invitation or no longer recruiting.

TRIAL PHASE Definitions
source:  https://clinicaltrials.gov/ct2/about-studies/glossary#P

Food and Drug Administration (FDA) categories for describing the clinical trial of a drug based on the study's characteristics, such as the objective and number of participants. There are five phases:
Early Phase 1: Exploratory study involving very limited human exposure to the drug, with no therapeutic or diagnostic goals (for example, screening studies, microdose studies)
Phase 1: Studies that are usually conducted with healthy volunteers and that emphasize safety. The goal is to find out what the drug's most frequent and serious adverse events are and, often, how the drug is metabolized and excreted.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition). For example, participants receiving the drug may be compared with similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing. These including postmarket requirement and commitment studies that are required of or agreed to by the sponsor. These studies gather additional information about a drug's safety, efficacy, or optimal use.

8 cognitive therapy trials as of 5/21/19

PHASE 2

6 gene therapy trials as of 5/21/19

* includes interventions such as exercise, physical therapy, speech therapy, dietary supplements.

67 DBS-related trials as of 5/21/19

To view publications of completed studies, you can search PubMed to find publication abstracts and authors, as well as links to full publications. Helpful keywords to use in a search are trial name, trial NCT# (i.e., ClinicalTrials.gov trial ID), principal investigator name, and sponsor name.  PubMed is a free resource developed by the National Center for Biotechnology Information (NCBI) at the U.S. NIH.    

PHASE 1

69 exercise-related trials as of 5/21/19

Parkinson's Disease interventional studies

      CLINICAL TRIALS BY PHASE and RECRUITING STATUS